Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02211755 · ClinicalTrials.gov registry record · Phase 1
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02211755: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT02211755 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02211755, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Background: \- Researchers want to develop better ways to treat cancer. In this study, they will give people with cancer two drugs. These drugs have been used on their own to treat some blood cell cancers. Objectives: \- To test the safety and efficacy of the drug combination of bortezomib and clofarabine. Eligibility: \- Adults age 18 and over with advanced cancer that has progressed after receiving standard treatment or that has no effective therapy. Design: * Participants will be screened with medical history, physical exam, and scans to measure their tumors. They will also have heart, blood, and urine tests. All of these may be done by their regular doctors. * Participants will get the study drugs in 21-day cyles. They will stay at the clinic for week 1 of every cycle, then have 2 weeks off. \<TAB\>- Bortezomib will be injected under the skin on days 1 and 4. \<TAB\>- Clofarabine will be injected in a vein for days 1-5. * During cycle 1 only, participants will go to the clinic or their doctor to have a physical exam and blood tests at the start of the second and third week. * Participants will have clinical evaluations throughout the study, including before receiving treatment and then before the start of each cycle. * Participants may stay in the study as long as they are tolerating the drugs and their tumor is not getting worse. * Participants will have follow-up for 30 days after the last dose of study drugs. * The first part of this study tests the safety of different doses of clofarabine and bortezomib. * The second part of this study involves a separate group of participants who will undergo mandatory research biopsies to learn more about the effects of clofarabine and bortezomib on cancer cells.
Interventions
- DRUG Bortezomib plus Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2014-10-06 |
| Est. Completion | 2025-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02211755
The ClinicalTrials.gov registry entry for NCT02211755 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bortezomib plus Clofarabine is the first listed.
NCT02211755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02211755 about?
NCT02211755 is a clinical study titled "Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors". Background: \- Researchers want to develop better ways to treat cancer. In this study, they will give people with cancer two drugs. These drugs have been used on their own to treat some blood cell cancers. Objectives: \- To test the safety and efficacy of the drug combination of bortezomib and cl...
What is the current status of trial NCT02211755?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2014-10-06. Estimated completion is 2025-08-15.
What interventions are being tested in trial NCT02211755?
The interventions under investigation include: Bortezomib plus Clofarabine (DRUG).
Who is sponsoring clinical trial NCT02211755?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.